Development of immunotoxins for potential clinical use in Hodgkin's disease

Publisher Website
Google Scholar
Abstract
During the last decade, immunotoxins (ITs) consisting of a cell-binding moiety and a potent toxin were developed as a new class of biological anti-tumor agents. Hodgkin's disease has shown to be one of the best targets for immunotoxins, as lymphocyte activation markers such as CD25 and CD30 are expressed on Hodgkin and Reed-Sternberg (H-RS)-cells in large numbers. Several inimunotoxins against these antigens, which are expressed physiologically only on a small subset of activated hematopoietic cells have demonstrated potent antitumor effects both, in vitro and in animal models. Here we summarize the experimental and recent clinical data of using ifs in Hodgkin's disease.

This publication has 40 references indexed in Scilit: